scholarly journals The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: A six-month, longitudinal, observational, multicenter study

2005 ◽  
Vol 52 (8) ◽  
pp. 2506-2512 ◽  
Author(s):  
Marte S. Heiberg ◽  
Bjørn-Yngvar Nordvåg ◽  
Knut Mikkelsen ◽  
Erik Rødevand ◽  
Cecilie Kaufmann ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Ankylosing Spondylitis ◽  
Tumor Necrosis Factor ◽  
Multicenter Study ◽  
Comparative Effectiveness ◽  
Tumor Necrosis ◽  
Blocking Agents ◽  
Necrosis Factor

scholarly journals Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry

2019 ◽  
Vol 6 (2) ◽  
pp. 217-230 ◽  
Author(s):  
Leslie R. Harrold ◽  
Heather J. Litman ◽  
Sean E. Connolly ◽  
Evo Alemao ◽  
Sheila Kelly ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
United States ◽  
Tumor Necrosis Factor ◽  
Comparative Effectiveness ◽  
Tumor Necrosis ◽  
The United States ◽  
Tumor Necrosis Factor Inhibitors ◽  
Necrosis Factor

FRI0427 Tumor necrosis factor blocking agents inhibit the progression of preclinical atherosclerosis in patients with ankylosing spondylitis

2013 ◽  
Vol 72 (Suppl 3) ◽  
pp. A519.1-A519 ◽  
Author(s):  
A. M. Van Sijl ◽  
I. C. van Eijk ◽  
M. J. Peters ◽  
E. H. Serne ◽  
I. H. van der Horst-Bruinsma ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Blocking Agents ◽  
Preclinical Atherosclerosis ◽  
Necrosis Factor

AB0474 Comparison of drug retention rates between anti-tumor necrosis factor agents in rheumatoid arthritis and ankylosing spondylitis in daily clinical practice:

2013 ◽  
Vol 71 (Suppl 3) ◽  
pp. 664.14-665 ◽  
Author(s):  
J.M. Senabre-Gallego ◽  
J. Rosas ◽  
G. Santos-Soler ◽  
C. Santos-Ramírez ◽  
M. Sánchez-Barrioluengo ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Practice ◽  
Ankylosing Spondylitis ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Daily Clinical Practice ◽  
Retention Rates ◽  
Drug Retention ◽  
Necrosis Factor

scholarly journals Direct Comparative Effectiveness Among 3 Anti–Tumor Necrosis Factor Biologics in a Real-Life Cohort of Patients With Rheumatoid Arthritis

2016 ◽  
Vol 22 (2) ◽  
pp. 57-62 ◽  
Author(s):  
Pedro Santos-Moreno ◽  
Guillermo Sánchez ◽  
Danny Gómez ◽  
Juan Bello-Gualtero ◽  
Carlos Castro
Keyword(s):  
Rheumatoid Arthritis ◽  
Tumor Necrosis Factor ◽  
Comparative Effectiveness ◽  
Tumor Necrosis ◽  
Real Life ◽  
Necrosis Factor

Efficacy of golimumab in the treatment of ankylosing spondylitis and rheumatoid arthritis (own experience)

2020 ◽  
Vol 5-6 (215-216) ◽  
pp. 24-31
Author(s):  
Madina Murzabayeva ◽  
Keyword(s):  
Rheumatoid Arthritis ◽  
Ankylosing Spondylitis ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Human Monoclonal Antibody ◽  
Laboratory Data ◽  
Das 28 ◽  
Tnf Α ◽  
Necrosis Factor

Genetic engineering drugs are used to treat rheumatic diseases. Based on the results of multicenter studies, the effectiveness and safety of golimumab, a representative of the group of tumor necrosis factor inhibitors in various categories of patients, was proved.. Purpose of research.To evaluate the effectiveness of golimumab in the treatment of ankylosing spondylitis and rheumatoid arthritis. Material and methods. The efficacy of golimumab was analyzed based on clinical and laboratory data in 7 patients with ankylosing spondylitis and 6 patients with rheumatoid arthritis. These studies are described against the background of a one-year follow-up of patients. Results and discussion. The observation group consisted of 7 patients with ankylosing spondylarthritis (as) and 6 patients with a diagnosis of rheumatoid arthritis. In all patients with (as) at the beginning of the study, the BASDAI index >6 points, and in 5 patients, the ASDASRB index was 3.5±0.45. In 4 patients with the diagnosis (as), the BASFI index was 7±0.67, and in three patients-5±0.3. the BASMI Index in all studied patients revealed pronounced disorders and was 7.5±0.85. Positive dynamics was observed during golimumab therapy. A patient with a high degree of BASDAI activity >6 showed improvement on the 4th injection of golimumab, the Average score of BASDAI and BASFI indices on golimumab was lower by the 20th week, compared with the start of therapy. By the 24th week of therapy, the BASDAI index was down 31%. The follow-up group with the diagnosis of rheumatoid arthritis consisted of 6 patients, including 1 male and 5 female, with an average age of 38±0.5 years. In a male patient, the DAS-28 index was 5.2±0.06, the SDAI index was 27±0.05, and the CDAI index was 23±0.03. In women, the DAS-28 index was 3.8±0.03, and the SDAI index was 19±0.3 in 5 patients, and the CDAI index was 20±0.3. after adding golimumab, the General condition of all patients improved clinically after the second injection, and all indicators of inflammatory activity decreased. Golimumab is a human monoclonal antibody to tumor necrosis factor (TNF)α. The effect of golimumab is due to the binding and neutralization of soluble and membrane-bound forms of TNF)α. TNF)α. it is a cytokine detected in patients with rheumatoid arthritis, ankylosing spondylarthritis. Conclusion. Against the background of the use of golimumab, the clinical effect was noted in the form of complete relief of joint pain and positive dynamics according to the studied laboratory parameters. Keywords: rheumatoid arthritis, ankylosing spondylitis, golimumab, efficacy.

Sign in / Sign up

Export Citation Format

Share Document